Benzinga

Search documents
Stock Of The Day: Can Prime Day Propel Amazon To New Heights?
Benzinga· 2025-07-11 19:21
Group 1 - Amazon's stock is currently testing the top of its recent trading range, which could lead to a significant upward movement if broken [1][6] - The previous support level around $217.50 was established in December and January, but it was broken in February, leading to a decline in stock price [2][4] - A large concentration of sellers formed resistance at the previous support level when the stock rallied back to this price in June, causing hesitation among buyers [4][5] Group 2 - In late June, buyers overcame the sellers, breaking the resistance and turning it into a new support level, indicating a potential shift in market sentiment [5][6] - The current resistance level is around $224, and if this is broken, it suggests that sellers have exited the market, paving the way for new buyers [6][7] - With reduced supply in the market, new buyers may need to push prices higher, potentially establishing a new uptrend for Amazon's stock [7]
M&T Bank Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Benzinga· 2025-07-11 18:37
Earnings Report - M&T Bank Corporation is set to release its second-quarter earnings results on July 16, with analysts expecting earnings of $4.00 per share, an increase from $3.79 per share in the same period last year [1] - The projected quarterly revenue is $2.39 billion, compared to $2.3 billion a year earlier [1] Partnership Development - On June 5, M&T Bank and the Galesi Group announced a partnership aimed at revitalizing Schenectady's Mohawk Harbor [2] - Following the announcement, M&T Bank shares rose by 1.8%, closing at $204.05 [2] Analyst Ratings - Citigroup analyst Keith Horowitz maintained a Neutral rating and raised the price target from $200 to $212 [5] - Morgan Stanley analyst Manan Gosalia maintained an Overweight rating and increased the price target from $206 to $215 [5] - RBC Capital analyst Gerard Cassidy reiterated an Outperform rating with a price target of $200 [5] - Truist Securities analyst Brian Foran maintained a Buy rating but reduced the price target from $225 to $200 [5] - RBC Capital analyst Brad Erickson maintained an Outperform rating and lowered the price target from $208 to $200 [5]
Crude Oil Rises Sharply; Milestone Pharmaceuticals Shares Plunge
Benzinga· 2025-07-11 18:37
Market Overview - U.S. stocks traded mostly lower, with the Dow Jones index dropping over 250 points, down 0.60% to 44,382.58, while the NASDAQ rose slightly by 0.06% to 20,643.06, and the S&P 500 fell 0.23% to 6,266.23 [1] - European shares were lower, with the eurozone's STOXX 600 dipping 1.07%, Spain's IBEX 35 Index falling 0.99%, London's FTSE 100 down 0.47%, Germany's DAX 40 slipping 0.81%, and France's CAC 40 declining 0.94% [5] - Asian markets closed mixed, with Japan's Nikkei down 0.19%, Hong Kong's Hang Seng up 0.46%, China's Shanghai Composite gaining 0.01%, and India's BSE Sensex falling 0.83% [6] Company Earnings - WD-40 Co. (WDFC) reported better-than-expected earnings for its third quarter, although sales missed estimates. The company raised its FY2025 EPS guidance but narrowed its sales forecast [2] Stock Movements - MiNK Therapeutics, Inc. (INKT) shares surged 526% to $48.40 following a publication in Oncogene [8] - Ruanyun Edai Technology Inc. (RYET) shares increased by 19% to $18.37 after signing a strategic partnership with Confucius Institute at Prince Sultan University [8] - Signing Day Sports, Inc. (SGN) shares rose 98% to $2.4350 due to advancements in its business combination with One BlockchAIn [8] - Milestone Pharmaceuticals Inc. (MIST) shares dropped 41% to $1.5050 after announcing a public offering [8] - Federal Agricultural Mortgage Corporation (AGM) shares fell 11% to $175.20 following the announcement of the departure of its Chief Financial Officer [8] - TransMedics Group, Inc. (TMDX) shares decreased by 10% to $112.93 [8] Commodities - In commodity news, oil prices increased by 2.6% to $68.28, gold rose by 1.5% to $3,375.80, silver gained 4.1% to $38.830, while copper fell by 0.9% to $5.5425 [4]
Expedia Gears Up For Takeoff As Travel Bookings Bounce Back
Benzinga· 2025-07-11 18:35
Core Viewpoint - Expedia Group Inc. is experiencing renewed optimism from Wall Street due to signs of a rebound in U.S. travel demand, with Bank of America Securities maintaining a Buy rating and a price forecast of $211 [1]. Group 1: Market Trends and Performance - A mild recovery in U.S. bookings during the summer and shoulder season is expected to catalyze Expedia's stock performance, which is closely linked to the domestic travel market [1]. - Recent trends since April have stabilized, leading to fewer downside risks to estimates for the company [2]. - U.S. air travel data shows year-over-year declines, with June airline spending down 10.9% and lodging spending down 3.5%, indicating a deceleration from May [5]. Group 2: Growth Drivers - Key tailwinds for Expedia include continued growth in its B2B and advertising segments, supported by new airline partnerships with Southwest Airlines and Ryanair [3]. - EBITDA is projected to grow by 7% in 2025, based on conservative 2% growth from the B2C segment, which is reasonable given the company's flat U.S. and 33% international exposure [3]. Group 3: Financial Health and Valuation - Expedia has a strong free cash flow profile and buyback potential, with estimates suggesting the company could repurchase about 10% of its shares over the next year, excluding dividends [4]. - The stock is currently trading at 5.8x estimated 2026 EBITDA and 9x expected 2026 free cash flow, which are considered attractive valuations [4].
JPMorgan Just Hit 'Delete' On Tesla And Rivian
Benzinga· 2025-07-11 18:16
Group 1: Core Insights - JPMorgan analyst Ryan Brinkman has identified Tesla Inc and Rivian Automotive Inc as top short ideas for the second half of 2025 due to high valuations, decreasing subsidies, and a disconnect between market expectations and reality [1][5] Group 2: Tesla Analysis - Tesla is currently trading at a forward earnings multiple of 142x, significantly higher than the average of 25.2x for the Magnificent 7 [2] - JPMorgan forecasts a third consecutive year of earnings per share (EPS) declines for Tesla, attributed to thinner margins, reduced government subsidies, and challenges with its robotaxi initiative [3] Group 3: Rivian Analysis - Rivian is trading just above $13, facing significant cash burn and challenges due to slashed EV subsidies and rising tariffs, which may hinder its ability to reduce EBITDA losses and free cash outflows [4] Group 4: Industry Outlook - The electric vehicle (EV) market is experiencing economic challenges, with diminishing government support and increasing competition, suggesting that investors may be overvaluing current EV stocks based on future expectations [5]
Joby Aviation Stock Goes Vertical As Secret, Massive Drone Achieves 9-Hour Flight
Benzinga· 2025-07-11 17:58
Core Insights - Joby Aviation's shares have increased nearly 30% over the past month, driven by positive developments regarding its new hydrogen-powered UAV, the JAI 30 [1][4] - The JAI 30 has reportedly achieved a flight endurance of over nine hours, positioning it among the longest-endurance hydrogen-powered UAVs [2][3] - Joby is conducting test flights for the JAI 30 at the Pendleton UAS Range in Oregon, a significant unmanned aircraft testing center in the U.S. [3][4] Company Developments - Joby Aviation has not publicly announced the JAI 30 model, but evidence suggests active flight operations with ground crews and hydrogen tanks present [2][4] - The company has successfully completed piloted vertical-takeoff-and-landing flights of its electric air taxi in Dubai, aiming for commercial air taxi services by 2026 [5] - Joby Aviation's stock has gained over 50% this year due to a series of positive news catalysts [4][6] Industry Context - The advanced air mobility sector received a boost from FAA Acting Administrator Chris Rocheleau's positive comments on integrating new aircraft into U.S. airspace [5][6] - The JAI 30's nine-hour flight time does not surpass the 30-hour record set by a lighter Chinese UAV, indicating competitive dynamics in the UAV market [3]
Why Is Gulfport Energy Stock Soaring On Friday?
Benzinga· 2025-07-11 17:35
Core Viewpoint - Gulfport Energy Corporation's stock is experiencing a nearly 5% increase as investors anticipate strong second-quarter earnings due to a strategic reevaluation of capital spending plans [1] Group 1: Strategic Changes - The company is reallocating resources towards dry gas development, including the addition of a four-well dry gas Utica pad, while adjusting the schedule for its wet gas Marcellus pad [1][4] - This proactive approach may allow Gulfport to accelerate completions if natural gas market conditions remain favorable, potentially leading to low single-digit growth in 2026 [2][6] Group 2: Analyst Outlook - JP Morgan analyst Zach Parham has reiterated an Overweight rating on Gulfport Energy, raising the price forecast from $208 to $236, anticipating a robust second quarter [3][4] - Parham estimates cash flow per share (CFPS) at $11.07, slightly above the Street estimate of $10.77, with EBITDA forecasted at $208 million, modestly below the consensus of $223 million [6] Group 3: Production and Financials - Estimated production is projected at 1,037 MMcfe/d, representing a 12% sequential increase, with oil output expected at 8.1 MBo/d, exceeding the 7.0 MBo/d consensus [7] - Capital expenditures for the quarter are expected to be around $124 million, slightly exceeding consensus, with an anticipated $65 million in free cash flow, of which $58 million is allocated to share buybacks [7][8]
AMC Stock Just Got Upgrade — Could Premium Screens, Box Office Momentum Signal A Comeback?
Benzinga· 2025-07-11 17:20
Core Viewpoint - AMC Entertainment's stock has surged following an upgrade from Wedbush analyst Alicia Reese, who raised the price forecast and highlighted the company's potential for improved box office performance due to a steadier film release schedule [1] Group 1: Market Position and Growth Potential - The company is well-positioned to gain market share in 2025 and 2026, benefiting from owning the highest number of premium screens in North America and expansion efforts in the U.K. and EU [2] - AMC plans to shut down unprofitable locations while investing in top-performing theaters, which is already boosting revenue per screen, currently tracking 3% above 2019 levels [4] - The analyst projects mid-to-high single-digit growth in box office revenue over the next few years, followed by low-to-mid single-digit gains thereafter [5] Group 2: Financial Performance and Projections - AMC has repaid or deferred all debt due in 2026, easing near-term financial uncertainty, and is finishing its last major share issuance for the foreseeable future [3] - The second-quarter revenue forecast has been revised to $1.35 billion, up from a prior estimate of $1.25 billion, exceeding the consensus of $1.337 billion [7] - AMC continues to generate $22–$23 in domestic revenue per attendee and about $16 internationally, both approximately 30% higher than pre-pandemic levels [8] Group 3: Operational Efficiency - EBITDA is expected to cover interest expenses, reducing the need for AMC to issue more equity [4] - The company has room to grow by expanding merchandise sales and improving concession revenue per customer [5] - North American box office for the second quarter reached 37.4%, with AMC capturing 22.0% of that total, down 50 basis points year-over-year [6]
Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?
Benzinga· 2025-07-11 16:33
Core Insights - MiNK Therapeutics, Inc. is experiencing a significant increase in stock price, with INKT stock rising 471.3% to $44.16 [7] - The company is focused on developing allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, with promising clinical results reported [2] Clinical Developments - A landmark case published in Nature's Oncogene reported a complete and durable remission in a patient with metastatic, treatment-refractory testicular cancer after receiving a single infusion of agenT-797 combined with Bristol-Myers Squibb's Opdivo [2][3] - The patient showed no evidence of disease over two years, with donor iNKT cells detectable for up to six months post-infusion, and the treatment was well-tolerated without severe side effects [4] - Data from a Phase 2 trial in 2L gastric cancer presented at the 2025 AACR Immuno-Oncology meeting indicated immune activation and early signs of tumor control in patients previously resistant to checkpoint inhibitors, with some patients surviving beyond 12 months [5] - A separate peer-reviewed case report noted a patient with metastatic gastric cancer achieving a 42% tumor reduction and over nine months of progression-free survival following a single infusion of agenT-797 combined with nivolumab [6] Market Activity - The trading volume for INKT stock reached 20.2 million, significantly higher than the average volume of 7.5 million [1]
Netflix's Squid Game Reality Show Gets Season 2 Date: $4.56 Million Prize Without The Killing
Benzinga· 2025-07-11 16:16
Netflix Inc. NFLX is giving fans of its smash-hit series "Squid Game" something new — but instead of a spinoff or new storyline, it's a second season of the reality competition.What Happened: After a record-breaking third and final season of "Squid Game," the main storyline of the hit show is done. Fans are hoping for spinoffs and a U.S. version of the show.While fans await those details, Netflix did share updates on the reality competition based on the hit show."Squid Game: The Challenge" will air a second ...